Short Q&A
- What did gene editing show in alpha-1 antitrypsin deficiency (AATD)?
In one patient, a single dose of liver-targeted base editing corrected 54–57% of affected alleles, with AAT production reported at 10 weeks. - Which investigational treatments reduced COPD exacerbations?
Tozorakimab reduced exacerbations by about 30%, and astegolimab by about 15%; neither showed meaningful improvements in symptoms or lung function. - How does COPD affect life expectancy?
In one cohort, estimated years of life lost ranged from 0.7 for GOLD stage 1 to 7 for GOLD stage 4 disease. - What did prehospital ECPR show for cardiac arrest?
It was associated with higher survival and favorable neurological outcomes in younger patients, though differences in heart rhythms may have influenced the results. - Does earlier vasopressin improve septic shock outcomes?
Starting it at a lower vasopressor threshold did not improve major outcomes compared with starting later. - What are key recent critical-care findings?
Isoflurane sedation had similar mortality to IV sedation; autonomous oxygen devices improved oxygenation; and bicarbonate did not reduce major kidney events in one trial. - What did studies suggest about ICU care and rehabilitation?
Telerehabilitation may improve some functional outcomes; a program starting during critical illness was associated with lower mortality in one trial. - What is the role of cryobiopsy?
Studies and expert guidance support its use for selected lung and lymph-node biopsies, particularly at experienced centers. - What new treatments showed promise in advanced lung cancer?
Several investigational combinations and antibody-drug conjugates improved outcomes in trials, but most still require regulatory review or further study. - What was reported for tarlatamab maintenance in extensive-stage small-cell lung cancer?
Adding it to durvalumab improved survival outcomes after initial treatment, but cytokine release syndrome was common. - What did recent pulmonary embolism studies find?
Catheter-directed thrombolysis reduced decompensation in intermediate-high-risk PE; the YEARS approach also showed potential for evaluating some patients with active cancer. - What did retatrutide do in obstructive sleep apnea?
In trials, it reduced apnea severity and helped more participants reach remission or mild disease, with gastrointestinal effects commonly reported. - What did a trial find about rituximab for EGPA maintenance?
It performed similarly to azathioprine on several outcomes but was associated with more severe infections.










